
Wednesday, July 02, 2025 4:20:32 PM
I wanted to share a deep dive I put together analyzing the current status of Hikma v. Amarin at the Supreme Court level and the likelihood of the Solicitor General supporting certiorari. It walks through the legal pathway, strategic implications, and potential impact on Amarin's value and positioning, especially in light of recent retail and legal community engagement (e.g., north40000's filings and Hazel-Atlas references). It analyzed all available legal documents I uploaded in the past year leading up to where we currently sit with the SG.
📄 Memo Title:
SCOTUS Analysis of Hikma v. Amarin and SG Certiorari Outlook
🔗 Link to Full Memo:
https://chatgpt.com/s/dr_685f825292dc8191851738b7cb8bbc36
Would love to hear the board's take, especially on how you all view the SG’s potential stance, the fraud angle that’s been raised, and what it could mean for AMRN's leverage in 2025.
Note: Please disregard the memo letterhead at the top. It was unintentionally formatted as a formal internal memorandum addressed to Amarin Pharma. The content that follows is an independent legal analysis prepared for discussion and strategic insight, not an internal company document.
If you guys like the format, I have many others prepared on various Amarin topics that you might find interesting or informative. Happy to share weekly.
— San Diego living
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2025 01:30:04 AM
- Amarin Stock Surges 11% After $25 Million Licensing Deal with Recordati • IH Market News • 06/24/2025 02:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/24/2025 11:05:28 AM
- Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe • GlobeNewswire Inc. • 06/24/2025 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2025 11:05:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2025 11:05:10 AM
- Amarin Reports First Quarter 2025 Financial Results • GlobeNewswire Inc. • 05/07/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2025 08:20:08 PM
- Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/29/2025 08:15:00 PM
- Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 • GlobeNewswire Inc. • 04/28/2025 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:03 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2025 10:00:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2025 09:01:21 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2025 11:30:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 11:35:08 AM
- Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change • GlobeNewswire Inc. • 04/09/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2025 11:25:08 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/07/2025 11:50:42 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM